

North Central Cancer Treatment Group

N0626, A Phase II Randomized Study of Pemetrexed With Sorafenib versus Pemetrexed Alone
as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Status Change – April 9, 2010

NOTICE OF STATUS CHANGE

This study is permanently closed to patient accrual effective Friday,
April 9, 2010. Patient entry will not be permitted after Thursday,
April 8, 2010 at 4:30 CST.

The accrual objective of this study has been met. Patients currently on
study should be followed according to the protocol.

Please retain this notice with the protocol.